Get started
Author

Jeffrey D. Isaacson

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
2017 · Robert L Coleman, Amit M Oza, et al. · The Lancet · 1,697
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
2016 · Elizabeth M Swisher, Kevin K Lin, et al. · The Lancet Oncology · 1,196
Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
2015 · Lecia V. Sequist, Jean-Charles Soria, et al. · New England Journal of Medicine · 662
PDF
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
2018 · Kevin K. Lin, Maria I. Harrell, et al. · Cancer Discovery · 434
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer
2007 · Michael A. Carducci, Fred Saad, et al. · Cancer · 294
A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2 -Mutated Ovarian Carcinoma or Other Solid Tumors
2017 · Rebecca Kristeleit, Geoffrey I. Shapiro, et al. · Clinical Cancer Research · 238
Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients
2001 · Dale J. Kempf, Jeffrey D. Isaacson, et al. · Journal of Virology · 232
Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
2013 · Elizabeth Poplin, Harpreet Wasan, et al. · Journal of Clinical Oncology · 160
PDF
Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and Pharmacokinetics
2002 · Michael A. Carducci, Joel B. Nelson, et al. · Journal of Clinical Oncology · 159
Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients
2002 · Ann Hsu, Jeffrey Isaacson, et al. · Antimicrobial Agents and Chemotherapy · 150
Analysis of the Virological Response with Respect to Baseline Viral Phenotype and Genotype in Protease Inhibitor-Experienced HIV-1-Infected Patients Receiving Lopinavir/Ritonavir Therapy
2002 · Dale J Kempf, Jeffrey D Isaacson, et al. · Antiviral Therapy · 123
PDF
Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: Phase 3 study
2004 · M. Carducci, J. B. Nelson, et al. · Journal of Clinical Oncology · 62
Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.
2003 · Bernard A Zonnenberg, Gerard Groenewegen, et al. · PubMed · 49
Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer
2005 · N. J. Vogelzang, J. B. Nelson, et al. · Journal of Clinical Oncology · 46
Correlation between Human Immunodeficiency Virus Genotypic Resistance and Virologic Response in Patients Receiving Nelfinavir Monotherapy or Nelfinavir with Lamivudine and Zidovudine
2000 · B. Atkinson, J. Isaacson, et al. · The Journal of Infectious Diseases · 41
Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: Translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody
2014 · Steffen Ormanns, Volker Heinemann, et al. · European Journal of Cancer · 36
Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors
2019 · Mingxiang Liao, Simon Watkins, et al. · Investigational New Drugs · 35
PDF
A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.
2013 · Rebecca Sophie Kristeleit, Geoffrey Shapiro, et al. · Journal of Clinical Oncology · 24
Evaluation of Drug–Drug Interactions of Rucaparib and CYP 1A2, CYP 2C9, CYP 2C19, CYP 3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor
2018 · Jim J. Xiao, Dorota Nowak, et al. · Clinical and Translational Science · 23
PDF
ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.
2014 · Elizabeth M. Swisher, Iain A. McNeish, et al. · Journal of Clinical Oncology · 12
A phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.
2014 · Jean-Charles Soria, Filippo G. De Braud, et al. · Journal of Clinical Oncology · 12
Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and a prospective evaluation of the of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment.
2013 · Elizabeth Poplin, Harpreet Wasan, et al. · Journal of Clinical Oncology · 12
Lack of correlation between SREBF1 genotype and hyperlipidemia in individuals treated with highly active antiretroviral therapy
2003 · Aiming Yang, Martin S King, et al. · AIDS · 12
Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC).
2016 · Jonathan Wade Goldman, Jean-Charles Soria, et al. · Journal of Clinical Oncology · 11
Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
2019 · Katrine Wallace, Sandra Goble, et al. · PharmacoEconomics · 9
PDF
Works count: 64
Citation count: 5,786
H-index: 19
I10-index: 24
Year
Topic
Type